Latest news with #TELA
Business Insider
4 days ago
- Business
- Business Insider
Tela Bio announces European launch of OviTex Inguinal Reinforced Tissue Matrix
TELA) announced the European launch of OviTex Inguinal Reinforced Tissue Matrix, the only reinforced tissue matrix specifically engineered for laparoscopic and robotic-assisted inguinal hernia repair. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
22-05-2025
- Business
- Yahoo
TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference
MALVERN, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the 2025 Jefferies Global Healthcare Conference. TELA's management is scheduled to present at the 2025 Jefferies Global Healthcare Conference at 11:05 am ET on June 5th, 2025. Interested parties can access the live and archived webcast at About TELA Bio, Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit Investor ContactLouisa Smithir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-03-2025
- Business
- Yahoo
TELA Bio Shares Drop 43% After Weak Q4 Growth, High Sales Turnover
TELA Bio (TELA, Financials) shares plunged 43% to $1.33 as of 11:43 a.m. Eastern Time on March 21 after the medical technology company reported a sharp slowdown in fourth-quarter growth and revealed high turnover within its sales force. Warning! GuruFocus has detected 3 Warning Signs with TELA. List of 52-Week Lows List of 3-Year Lows List of 5-Year Lows Down from a 26% increase in the previous quarter, income for the fourth quarter climbed 3.8% year over year to $17.6 million. The corporation blamed the delay down on storms, IV fluid shortages, and sales staff leaving-related disturbances. Revenue for 2024 full-year came in at $69.3 million, up 19% from 23% to 27% annual growth, TELA Bio anticipated 2025 sales between $85 million and $88 million. First-quarter income for the corporation falls between $17 million and $18 Bio claimed it adopted a redesigned commercial model splitting duties between Territory Managers and Account Specialists in order to handle sales interruptions. The corporation intends to grow the staff to 97 by year-end 2025; by the end of 2024 it claimed having 71 field representatives. In the fourth quarter, TELA Bio lost eleven Territory Managers; so, it is changing pay policies to handle retention performance shown some improvement. Launched in 2024, LiquiFix and OviTex IHR brought around roughly $1 million each. Larger OviTex PRS units and additional resorbable hernia options will help the business grow its range by from inventory changes, fourth-quarter gross margin dropped from 68% to 64% in the same time previous year. Travel and severance costs influenced sales and marketing spending totaling $14 million in the quarter. From $12.9 million year before, the net loss dropped to $9.2 million. The business has $52.7 million in cash reserves at year's from outside disturbances, analysts raised questions about continuous sales force turnover and recruitment challenges. Notwithstanding these challenges, TELA Bio stated it is still dedicated to following its expansion strategy and hopes to generate close-term annual revenue of $100 million. This article first appeared on GuruFocus. Sign in to access your portfolio
